Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors

Trial Profile

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Ribociclib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Therapeutic Use
  • Acronyms SIGNATURE
  • Sponsors Novartis
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 15 Apr 2018 to 31 Oct 2017.
    • 22 Sep 2017 Planned primary completion date changed from 15 Apr 2018 to 31 Oct 2017.
    • 08 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top